Solasia Pharma K.K Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Yoshihiro Arai
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 12yrs |
| CEO ownership | 0.5% |
| Management average tenure | 4.1yrs |
| Board average tenure | 7.4yrs |
Recent management updates
CEO
Yoshihiro Arai (64 yo)
12yrs
Tenure
Mr. Yoshihiro Arai has been the President, Chief Executive Officer and Representative Director at Solasia Pharma KK since February 2013. Mr. Arai served as Executive Vice President of Development of Solasi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 12yrs | no data | 0.53% ¥ 43.9m | |
| CFO, GM of Management Headquarters & Director | 11.1yrs | no data | 0.23% ¥ 18.9m | |
| Accounting Manager | no data | no data | no data | |
| Head of Marketing Division | 5.1yrs | no data | no data | |
| Head of Product Development Division | no data | no data | no data | |
| Head of Production Management Division | 3.1yrs | no data | no data | |
| Head of Reliability Assurance Division | 3.1yrs | no data | no data | |
| Head of Business Development Division | 1.1yrs | no data | no data |
4.1yrs
Average Tenure
Experienced Management: 4597's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 12yrs | no data | 0.53% ¥ 43.9m | |
| CFO, GM of Management Headquarters & Director | 9.2yrs | no data | 0.23% ¥ 18.9m | |
| Outside Audit & Supervisory Board Member | 4.9yrs | no data | no data | |
| Independent Outside Director | 10.2yrs | no data | no data | |
| Independent Outside Director | 8.8yrs | no data | no data | |
| Full-time Outside Audit & Supervisory Board Member | 5.9yrs | no data | no data | |
| Independent Outside Director | 4.9yrs | no data | no data | |
| Outside Audit & Supervisory Board Member | less than a year | no data | no data |
7.4yrs
Average Tenure
67yo
Average Age
Experienced Board: 4597's board of directors are considered experienced (7.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 17:02 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Solasia Pharma K.K. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nobumasa Morimoto | Mizuho Securities Co., Ltd. |
| Kyoichiro Shigemura | Nomura Securities Co. Ltd. |
| Dion Stéfan Büchner | Pathology Associates Co., Ltd. |